Table 4.
Fasting glucose, fasting insulin, HOMA IR and matsuda index
| Parameter | High dose OFS + P (N = 30) | Low dose OFS + P (N = 29) | Control (N = 29) |
|---|---|---|---|
|
Fasting glucose (mg/dl) | |||
| Baseline mean (SD) |
93.8 (10.41) |
94.2 (8.55) |
90.3 (10.00) |
| Week 3 mean (SD) |
90.9 (7.95) |
94.0 (7.71) |
91.5 (9.58) |
| Week 3 LS mean change adjusted for baseline |
−2.34 |
0.57 |
−0.06 |
| LS Mean difference from control (95% CI) |
−2.28 (−6.03, 1.46) |
0.63 (−3.15, 4.42) |
|
|
Fasting insulin (pmol/L) | |||
| Baseline geometric mean (SD log-scale) |
37.5 (0.59) |
40.6 (0.56) |
40.4 (0.49) |
| Week 3 geometric mean (SD log-scale) |
34.0 (0.52) |
37.8 (0.54) |
42.8 (0.61) |
| Week 3 geometric LS mean adjusted for baseline (SE log-scale) |
35.4 (0.07) |
37.0 (0.07) |
42.0 (0.07) |
| Geometric LS mean ratio relative to control (95% CI) |
0.84 (0.70, 1.01) |
0.88 (0.73, 0.1.06) |
|
|
Matsuda index |
|
|
|
| Baseline geometric mean (SD log-scale) |
11.5 (0.56) |
9.9 (0.55) |
10.4 (0.52) |
| Week 3 geometric mean (SD log-scale) |
11.7 (0.49) |
10.2 (0.53) |
8.8 (0.60) |
| Week 3 geometric LS mean adjusted for baseline (SE log-scale) |
10.9 (0.06) |
10.8 (0.06) |
9.0 (0.06) |
| Geometric LS mean ratio relative to control (95% CI) |
1.22 (1.04, 1.43) |
1.21 (1.03, 1.42) |
|
| |
(N = 25) |
(N = 25) |
(N = 26) |
|
HOMA-IR | |||
| Baseline geometric mean (SD log-scale) |
0.79 (0.506) |
0.87 (0.422) |
0.79 (0.447) |
| Week 3 geometric mean (SD log-scale) |
0.71 (0.404) |
0.78 (0.452) |
0.91 (0.507) |
| Week 3 geometric LS mean adjusted for baseline (SE log-scale) |
0.75 (0.067) |
0.78 (0.067) |
0.92 (0.066) |
| Geometric LS mean ratio relative to control (95% CI) | 0.82 (0.68, 0.98) | 0.85 (0.70, 1.02) | |
For fasting insulin, HOMA-IR and Matsuda Index log-transformation was required to improve distributional properties. The dependent variable in the ANCOVA was the log of the week 3 result. The LS means were adjusted for log of baseline, using an analysis of covariance model.